{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T20:37:16Z","timestamp":1770755836831,"version":"3.50.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-08974-4","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T08:45:29Z","timestamp":1752137129000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Changes in scanographic bone mineral density in melanoma patients treated with immunotherapy: a new irAE from real-life data"],"prefix":"10.1038","volume":"15","author":[{"given":"Soukayna","family":"Baddi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitri","family":"Suarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexis","family":"Ruet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Th\u00e9o","family":"Van Butsel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damiano","family":"Cerasuolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Christine","family":"Rat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Matthieu","family":"L\u2019Orphelin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,9]]},"reference":[{"key":"8974_CR1","unstructured":"Sant\u00e9 publique France"},{"key":"8974_CR2","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1158\/1078-0432.CCR-12-2625","volume":"19","author":"EJ Lipson","year":"2013","unstructured":"Lipson, E. J. et al. Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res Off J Am Assoc Cancer Res 19, 462\u2013468. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-2625 (2013).","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"8974_CR3","doi-asserted-by":"publisher","unstructured":"Recent Advances in the Treatment of Melanoma | New England Journal of Medicine. https:\/\/www.nejm.org\/doi\/full\/https:\/\/doi.org\/10.1056\/NEJMra2034861. Accessed 25 Jul 2024","DOI":"10.1056\/NEJMra2034861"},{"key":"8974_CR4","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/nature10673","volume":"480","author":"I Mellman","year":"2011","unstructured":"Mellman, I., Coukos, G. & Dranoff, G. Cancer immunotherapy comes of age. Nature 480, 480\u2013489. https:\/\/doi.org\/10.1038\/nature10673 (2011).","journal-title":"Nature"},{"key":"8974_CR5","doi-asserted-by":"publisher","first-page":"12293","DOI":"10.1073\/pnas.192461099","volume":"99","author":"Y Iwai","year":"2002","unstructured":"Iwai, Y. et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 99, 12293\u201312297. https:\/\/doi.org\/10.1073\/pnas.192461099 (2002).","journal-title":"Proc Natl Acad Sci U S A"},{"key":"8974_CR6","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","volume":"192","author":"GJ Freeman","year":"2000","unstructured":"Freeman, G. J. et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192, 1027\u20131034. https:\/\/doi.org\/10.1084\/jem.192.7.1027 (2000).","journal-title":"J Exp Med"},{"key":"8974_CR7","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow, M. A., Sidlow, R. & Hellmann, M. D. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378, 158\u2013168. https:\/\/doi.org\/10.1056\/NEJMra1703481 (2018).","journal-title":"N Engl J Med"},{"key":"8974_CR8","doi-asserted-by":"publisher","first-page":"4928","DOI":"10.3390\/cancers13194928","volume":"13","author":"J-M L\u2019Orphelin","year":"2021","unstructured":"L\u2019Orphelin, J.-M. et al. Severe late-onset grade III-IV adverse events under immunotherapy: A retrospective study of 79 cases. Cancers 13, 4928. https:\/\/doi.org\/10.3390\/cancers13194928 (2021).","journal-title":"Cancers"},{"key":"8974_CR9","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363, 711\u2013723. https:\/\/doi.org\/10.1056\/NEJMoa1003466 (2010).","journal-title":"N Engl J Med"},{"key":"8974_CR10","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s00280-016-3237-x","volume":"79","author":"N Yamazaki","year":"2017","unstructured":"Yamazaki, N. et al. Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041). Cancer Chemother Pharmacol 79, 651\u2013660. https:\/\/doi.org\/10.1007\/s00280-016-3237-x (2017).","journal-title":"Cancer Chemother Pharmacol"},{"key":"8974_CR11","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366, 2443\u20132454. https:\/\/doi.org\/10.1056\/NEJMoa1200690 (2012).","journal-title":"N Engl J Med"},{"key":"8974_CR12","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13613-019-0487-x","volume":"9","author":"V Lemiale","year":"2019","unstructured":"Lemiale, V. et al. Severe toxicity from checkpoint protein inhibitors: What intensive care physicians need to know?. Ann Intensive Care 9, 25. https:\/\/doi.org\/10.1186\/s13613-019-0487-x (2019).","journal-title":"Ann Intensive Care"},{"key":"8974_CR13","doi-asserted-by":"publisher","first-page":"657","DOI":"10.3389\/fimmu.2018.00657","volume":"9","author":"RK Srivastava","year":"2018","unstructured":"Srivastava, R. K., Dar, H. Y. & Mishra, P. K. Immunoporosis: Immunology of osteoporosis-role of T cells. Front Immunol 9, 657. https:\/\/doi.org\/10.3389\/fimmu.2018.00657 (2018).","journal-title":"Front Immunol"},{"key":"8974_CR14","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/125705","volume":"2013","author":"MN Weitzmann","year":"2013","unstructured":"Weitzmann, M. N. The role of inflammatory cytokines, the RANKL\/OPG axis, and the immunoskeletal interface in physiological bone turnover and osteoporosis. Scientifica 2013, 125705. https:\/\/doi.org\/10.1155\/2013\/125705 (2013).","journal-title":"Scientifica"},{"key":"8974_CR15","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s40425-018-0417-8","volume":"6","author":"KF Moseley","year":"2018","unstructured":"Moseley, K. F. et al. Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: A seminal case series. J Immunother Cancer 6, 104. https:\/\/doi.org\/10.1186\/s40425-018-0417-8 (2018).","journal-title":"J Immunother Cancer"},{"key":"8974_CR16","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1002\/ijc.33592","volume":"149","author":"DM Filippini","year":"2021","unstructured":"Filippini, D. M. et al. Bone fracture as a novel immune-related adverse event with immune checkpoint inhibitors: Case series and large-scale pharmacovigilance analysis. Int J Cancer 149, 675\u2013683. https:\/\/doi.org\/10.1002\/ijc.33592 (2021).","journal-title":"Int J Cancer"},{"key":"8974_CR17","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s00198-023-06690-1","volume":"34","author":"C Ye","year":"2023","unstructured":"Ye, C. et al. Fracture rate increases after immune checkpoint inhibitor treatment: A potential new immune related adverse event. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA 34, 735\u2013740. https:\/\/doi.org\/10.1007\/s00198-023-06690-1 (2023).","journal-title":"Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA"},{"key":"8974_CR18","doi-asserted-by":"publisher","unstructured":"Garbe, C., Amaral, T., Peris, K., et al. European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022. Eur J Cancer Oxf Engl 1990 170:236\u2013255. (2022) https:\/\/doi.org\/10.1016\/j.ejca.2022.03.008","DOI":"10.1016\/j.ejca.2022.03.008"},{"key":"8974_CR19","doi-asserted-by":"publisher","first-page":"588","DOI":"10.7326\/0003-4819-158-8-201304160-00003","volume":"158","author":"PJ Pickhardt","year":"2013","unstructured":"Pickhardt, P. J. et al. Opportunistic screening for osteoporosis using abdominal computed tomography scans obtained for other indications. Ann Intern Med 158, 588. https:\/\/doi.org\/10.7326\/0003-4819-158-8-201304160-00003 (2013).","journal-title":"Ann Intern Med"},{"key":"8974_CR20","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s11914-022-00764-5","volume":"21","author":"K Engelke","year":"2023","unstructured":"Engelke, K., Chaudry, O. & Bartenschlager, S. Opportunistic screening techniques for analysis of CT scans. Curr Osteoporos Rep 21, 65\u201376. https:\/\/doi.org\/10.1007\/s11914-022-00764-5 (2023).","journal-title":"Curr Osteoporos Rep"},{"key":"8974_CR21","doi-asserted-by":"publisher","first-page":"384","DOI":"10.3340\/jkns.2013.54.5.384","volume":"54","author":"S Lee","year":"2013","unstructured":"Lee, S., Chung, C. K., Oh, S. H. & Park, S. B. Correlation between bone mineral density measured by dual-energy X-Ray absorptiometry and hounsfield units measured by diagnostic CT in lumbar spine. J Korean Neurosurg Soc 54, 384. https:\/\/doi.org\/10.3340\/jkns.2013.54.5.384 (2013).","journal-title":"J Korean Neurosurg Soc"},{"key":"8974_CR22","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1007\/s00198-019-04931-w","volume":"30","author":"J Perrier-Cornet","year":"2019","unstructured":"Perrier-Cornet, J. et al. Opportunistic screening for osteoporosis using thoraco-abdomino-pelvic CT-scan assessing the vertebral density in rheumatoid arthritis patients. Osteoporos Int 30, 1215\u20131222. https:\/\/doi.org\/10.1007\/s00198-019-04931-w (2019).","journal-title":"Osteoporos Int"},{"key":"8974_CR23","doi-asserted-by":"publisher","DOI":"10.3171\/2022.11.SPINE22875","author":"N Deshpande","year":"2023","unstructured":"Deshpande, N. et al. Alternatives to DEXA for the assessment of bone density: A systematic review of the literature and future recommendations. J Neurosurg: Spine https:\/\/doi.org\/10.3171\/2022.11.SPINE22875 (2023).","journal-title":"J Neurosurg: Spine"},{"key":"8974_CR24","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s00198-024-07373-1","volume":"36","author":"C Ramsch\u00fctz","year":"2025","unstructured":"Ramsch\u00fctz, C. et al. Cervicothoracic volumetric bone mineral density assessed by opportunistic QCT may be a reliable marker for osteoporosis in adults. Osteoporos Int 36, 423\u2013433. https:\/\/doi.org\/10.1007\/s00198-024-07373-1 (2025).","journal-title":"Osteoporos Int"},{"key":"8974_CR25","doi-asserted-by":"publisher","first-page":"3013","DOI":"10.1002\/jor.24105","volume":"36","author":"M Burke","year":"2018","unstructured":"Burke, M. et al. Mechanical behavior of metastatic vertebrae are influenced by tissue architecture, mineral content, and organic feature alterations. J Orthop Res 36, 3013\u20133022. https:\/\/doi.org\/10.1002\/jor.24105 (2018).","journal-title":"J Orthop Res"},{"key":"8974_CR26","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/j.annonc.2023.10.001","volume":"34","author":"L Castelo-Branco","year":"2023","unstructured":"Castelo-Branco, L. et al. ESMO guidance for reporting oncology real-world evidence (GROW). Ann Oncol Off J Eur Soc Med Oncol 34, 1097\u20131112. https:\/\/doi.org\/10.1016\/j.annonc.2023.10.001 (2023).","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"8974_CR27","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","volume":"8","author":"HK Genant","year":"1993","unstructured":"Genant, H. K., Wu, C. Y., van Kuijk, C. & Nevitt, M. C. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res Off J Am Soc Bone Miner Res 8, 1137\u20131148. https:\/\/doi.org\/10.1002\/jbmr.5650080915 (1993).","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"key":"8974_CR28","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/s41416-019-0570-y","volume":"121","author":"S Danson","year":"2019","unstructured":"Danson, S. et al. Are we over-treating with checkpoint inhibitors?. Br J Cancer 121, 629\u2013630. https:\/\/doi.org\/10.1038\/s41416-019-0570-y (2019).","journal-title":"Br J Cancer"},{"key":"8974_CR29","doi-asserted-by":"publisher","first-page":"4625472","DOI":"10.1155\/2018\/4625472","volume":"2018","author":"C Vajaitu","year":"2018","unstructured":"Vajaitu, C. et al. The central role of inflammation associated with checkpoint inhibitor treatments. J Immunol Res 2018, 4625472. https:\/\/doi.org\/10.1155\/2018\/4625472 (2018).","journal-title":"J Immunol Res"},{"key":"8974_CR30","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41591-018-0221-5","volume":"25","author":"Z Wang","year":"2019","unstructured":"Wang, Z. et al. Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade. Nat Med 25, 141\u2013151. https:\/\/doi.org\/10.1038\/s41591-018-0221-5 (2019).","journal-title":"Nat Med"},{"key":"8974_CR31","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1148\/radiology.192.3.8058958","volume":"192","author":"G Guglielmi","year":"1994","unstructured":"Guglielmi, G., Grimston, S. K., Fischer, K. C. & Pacifici, R. Osteoporosis: diagnosis with lateral and posteroanterior dual x-ray absorptiometry compared with quantitative CT. Radiology 192, 845\u2013850. https:\/\/doi.org\/10.1148\/radiology.192.3.8058958 (1994).","journal-title":"Radiology"},{"key":"8974_CR32","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.3390\/diagnostics14242846","volume":"14","author":"M Chaisen","year":"2024","unstructured":"Chaisen, M. et al. Opportunistic screening for osteoporosis by CT as compared with DXA. Diagn Basel Switz 14, 2846. https:\/\/doi.org\/10.3390\/diagnostics14242846 (2024).","journal-title":"Diagn Basel Switz"},{"key":"8974_CR33","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/895474","volume":"2013","author":"N Li","year":"2013","unstructured":"Li, N. et al. Comparison of QCT and DXA: Osteoporosis detection rates in postmenopausal women. Int J Endocrinol 2013, 895474. https:\/\/doi.org\/10.1155\/2013\/895474 (2013).","journal-title":"Int J Endocrinol"},{"key":"8974_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006500","volume":"11","author":"CC Barron","year":"2023","unstructured":"Barron, C. C. et al. Chronic immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors: A systematic review. J Immunother Cancer 11, e006500. https:\/\/doi.org\/10.1136\/jitc-2022-006500 (2023).","journal-title":"J Immunother Cancer"},{"key":"8974_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102536","volume":"70","author":"P Gougis","year":"2024","unstructured":"Gougis, P. et al. Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade: A worldwide perspective. EClinicalMedicine 70, 102536. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102536 (2024).","journal-title":"EClinicalMedicine"},{"key":"8974_CR36","doi-asserted-by":"publisher","DOI":"10.1136\/bmjonc-2024-000398","volume":"3","author":"C Ye","year":"2024","unstructured":"Ye, C. et al. Increase in major osteoporotic fractures after therapy with immune checkpoint inhibitors. BMJ Oncol 3, e000398. https:\/\/doi.org\/10.1136\/bmjonc-2024-000398 (2024).","journal-title":"BMJ Oncol"},{"key":"8974_CR37","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s00198-023-06690-1","volume":"34","author":"C Ye","year":"2023","unstructured":"Ye, C. et al. Fracture rate increases after immune checkpoint inhibitor treatment: a potential new immune related adverse event. Osteoporos Int 34, 735\u2013740. https:\/\/doi.org\/10.1007\/s00198-023-06690-1 (2023).","journal-title":"Osteoporos Int"},{"key":"8974_CR38","doi-asserted-by":"publisher","first-page":"4980","DOI":"10.1007\/s00330-019-06018-w","volume":"29","author":"MT L\u00f6ffler","year":"2019","unstructured":"L\u00f6ffler, M. T. et al. Improved prediction of incident vertebral fractures using opportunistic QCT compared to DXA. Eur Radiol 29, 4980\u20134989. https:\/\/doi.org\/10.1007\/s00330-019-06018-w (2019).","journal-title":"Eur Radiol"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-08974-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-08974-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-08974-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T08:45:29Z","timestamp":1752137129000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-08974-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,9]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["8974"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-08974-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,9]]},"assertion":[{"value":"12 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jean-Matthieu L\u2019Orphelin has received speaker and consultant honoraria from BMS, Novartis, MSD and Pierre Fabre Oncology.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by CLERS, the Local Research Ethics Committee for Health (Ethics Approval Number: ID 4977). Analyses performed are available requesting corresponding author.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"As a retrospective study, all patient files were checked for non-objection.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Each participant provided non opposition.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}],"article-number":"24600"}}